di , 17/05/2024

In a strategic move to bolster its position in cutting-edge medical devices, Samsung Medison, a global medical equipment company and subsidiary of Samsung Electronics, has officially announced its acquisition of Sonio SAS, a leading fetal ultrasound AI software company.

Founded in 2020 with a mission to advance women and children’s health worldwide through medical innovations, Sonio has developed innovative IT solutions and AI features specifically tailored for obstetrics and gynecology ultrasound procedures. One of its flagship offerings, Sonio Detect, an FDA 510(k)-cleared AI assistant, utilizes sophisticated deep learning networks to ensure real-time image enhancement and elevate clinical accuracy, ultimately improving the quality of patient care.

Following the successful acquisition, Sonio will operate as an independent entity based in France, maintaining its autonomy in commercial expansion while ensuring the compatibility of its solutions with ultrasound devices from various manufacturers. By harnessing Samsung Medison’s expertise in ultrasound systems and combining it with Sonio’s cutting-edge AI capabilities, the collaboration aims to introduce groundbreaking AI-enhanced workflows that will drive significant advancements in patient outcomes and the quality of prenatal care.

Yong Kwan Kim, CEO of Samsung Medison, expressed enthusiasm about the partnership, stating, “Through the acquisition of Sonio, Samsung Medison remains committed to leveraging technology to enhance people’s lives. This collaboration holds the potential to revolutionize prenatal ultrasound examinations with state-of-the-art AI technology and reporting functionalities.

Meanwhile, Cécile Brosset, CEO of Sonio, highlighted the synergistic benefits of the acquisition, emphasizing the growth opportunities it presents for both companies. “The partnership with Samsung Medison marks an exciting chapter in our journey to advance medical reporting technology and diagnostic software on a global scale. Together, we aim to drive innovation and address healthcare needs, including in underserved regions,” said Brosset.

The completion of the acquisition is contingent upon regulatory approvals, including the green light from the French Ministry of the Economy and Finance. As both companies gear up to combine their expertise and resources, the collaboration between Samsung Medison and Sonio sets the stage for transformative developments in the field of obstetrics and gynecology, ultimately enhancing patient care and medical diagnostics worldwide.